Combining GABA with the GLP-1 agonist liraglutide reversed diabetes, restored insulin secretion, and fully normalized pancreatic islet architecture in a rat model of Wolfram syndrome.
Complete islet restorationThe GABA-liraglutide combination fully restored pancreatic islet architecture and normalized the ratio of alpha, beta, and delta cells — something neither treatment achieved alone.
What the researchers found
In Wolfram syndrome rats, GABA monotherapy had no significant effect on diabetes, while liraglutide monotherapy (0.4 mg/kg/day) effectively delayed progression. However, the GABA (1 g/kg/day) plus liraglutide combination reversed the diabetic phenotype entirely: glucose homeostasis was significantly enhanced, insulin and C-peptide secretion improved, and beta-cell mass increased.
Remarkably, the combination therapy fully restored Langerhans islet architecture, correcting the intra-islet ratio of alpha, beta, and delta cells to normal proportions. Both liraglutide alone and combination therapy increased GAD65/67-positive beta cells, indicating improved beta-cell health, but only the combination achieved complete phenotype reversal.
Why it matters
Wolfram syndrome currently has no approved treatments, and patients face progressive diabetes, blindness, and neurodegeneration. Finding that a readily available combination — a GLP-1 drug already on the market plus GABA (a dietary supplement) — can reverse the diabetic phenotype and restore pancreatic tissue offers hope for a condition that has had virtually no therapeutic options.
How the study worked
Five-month-old glucose-intolerant Wolfram syndrome rats and wild-type littermates received daily treatment with GABA (1 g/kg/day), liraglutide (0.4 mg/kg/day), or both for four months. Diabetes was monitored via intraperitoneal glucose tolerance tests with insulin and hormone measurements by ELISA. Post-treatment immunohistochemistry assessed islet morphology, cellular distribution, and beta-cell health markers.
What this study cannot tell us
This is a rat model study, and Wolfram syndrome in rats may not perfectly replicate the human disease. The sample sizes typical of rare disease animal models are small. Four months of treatment may not predict lifelong outcomes. GABA dosing at 1 g/kg/day is very high and may not be practical in humans. The mechanisms underlying the synergistic effect were not fully elucidated.
How to read the evidence
This is a preclinical animal study in a rat model of a rare genetic disease. While the results are striking — complete reversal of the diabetic phenotype — translation to human Wolfram syndrome patients requires clinical trials. The rare disease context makes animal model evidence particularly important given the difficulty of conducting large human studies.
When this study was published
Published in 2025, this is very current research and one of the first studies to explore GABA supplementation in Wolfram syndrome. It provides timely support for combination therapy clinical trials.
The bigger picture
This study sits at the intersection of rare disease research and GLP-1 peptide therapeutics. While GLP-1 agonists are primarily known for type 2 diabetes and obesity, their potential in rare genetic forms of diabetes like Wolfram syndrome could expand their clinical reach. The synergy with GABA — which alone was ineffective — demonstrates that combination approaches may unlock therapeutic benefits impossible with single agents, a principle applicable across peptide medicine.
Questions still open
- What is the mechanism behind the synergy between GABA and liraglutide that makes the combination so much more effective than either alone?
- Would this combination also slow the neurodegeneration and vision loss associated with Wolfram syndrome?
- Can the GABA + GLP-1 agonist combination benefit other rare genetic forms of diabetes beyond Wolfram syndrome?
Common questions
What is Wolfram syndrome and why is it so difficult to treat?
Why did GABA only work when combined with liraglutide?
Read the original research
GABA and GLP-1 receptor agonist combination therapy modifies diabetes and Langerhans islet cytoarchitecture in a rat model of Wolfram syndrome.
Diabetology & metabolic syndrome, 17(1), 82
Citation
Jagomäe, Toomas; Velling, Sandra; Tikva, Tessa Britt; Maksimtšuk, Varvara; Gaur, Nayana; Reimets, Riin; Kaasik, Allen; Vasar, Eero; Plaas, Mario. (2025). GABA and GLP-1 receptor agonist combination therapy modifies diabetes and Langerhans islet cytoarchitecture in a rat model of Wolfram syndrome.. Diabetology & metabolic syndrome, 17(1), 82. https://doi.org/10.1186/s13098-025-01651-6